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INTRODUCTION
Endometriosis is defined as the presence of endometrial
tissue outside the uterus. The most common sites affected
are the ovaries, uterine ligaments, recto- and vesico-vaginal
septae, pelvic peritoneum, cervix, labia and vagina. Malig-
nant transformation of endometriosis may occur in up to
1% of women, with the most common site being the ovary
(1). The risk of ovarian cancer increases among patients with
a long history of ovarian endometrioma (2), and the malig-
nant transformation of endometriosis may be affected by the
hormonal changes associated with menopause (3, 4) Endo-
metriosis is present in 10% to 15% of patients with ovarian
cancer, with the most common extra-ovarian site of neoplas-
tic transformation being the rectovaginal septum (5). Forty
patients with endometriosis-associated intestinal tumors have
been reported (6-7), but malignant transformation of endo-
metriosis in the uterine cervix is exceedingly rare. 
In this report, we describe a woman with endometrioid
adenocarcinoma arising from endometriosis of the uterine
cervix. In addition, we review the literature on this condition,
and discuss the prognostic factors and the most appropriate
therapeutic approaches.
CASE REPORT
A 48-yr-old woman complaining of severe dysmenorrhea
was referred for investigation of a pelvic mass. She was oth-
erwise well, was not taking hormone medication, and had a
body mass index of 24.4 kg/m2. A cervical smear revealed
benign cellular changes. Magnetic resonance imaging showed
an image typical of an endometrial cyst of the uterine cervix,
with high intensity in T1W1 and T2W1, a smooth surface,
and shading. Adenomyosis was observed in the body of the
uterus, but there was no evidence of enlarged lymph nodes
or ascites (Fig. 1). Her serum concentration of CA125 was
359 U/mL (normal <35 U/mL). At the time of laparotomy,
she had an enlarged uterus (12×7×6 cm3), which weighed
231 g, and her uterine cervix was enlarged to the size of an
egg, with multiple round masses. Severe adhesion was observed,
with endometrial tissue in the posterior wall of the uterus and
the peritoneum and total posterior cul-de-sac obliteration. The
left ovary was adherent to the posterior surface of the uterus,
with a dark brownish cyst typical of an endometrial cyst. Total
abdominal hysterectomy and bilateral salpingo-oophorecto-
my with adhesiolysis were performed, and the specimens were
submitted for frozen section analysis. The extra-ovarian lesi-
ons were electrically cauterized. Pathologic examination of
the frozen sections suggested an adenocarcinoma arising from
endometriosis in the cervical wall. 
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Endometrioid Adenocarcinoma Arising from Endometriosis of the
Uterine Cervix: A Case Report
Endometrioid adenocarcinoma arising from endometriosis of the uterine cervix is
rare in premenopausal woman. We describe here a patient with this condition and
review the clinical and pathological features of these tumors. A 48-yr-old woman
complaining of severe dysmenorrhea was referred for investigation of a pelvic mass.
Total abdominal hysterectomy and bilateral salpingo-oophorectomy were performed.
Histological examination revealed an endometrioid adenocarcinoma directly adja-
cent to the endometriosis at the uterine cervix, with a transition observed between
endometriosis and endometrioid adenocarcinoma. The patient was diagnosed as
having endometrioid adenocarcinoma arising from endometriosis of the uterine cervix
and underwent postoperative chemotherapy. Gynecologists and pathologists should
be aware of the difficulties associated with a delay in diagnosis of endometrioid ad-
enocarcinoma arising from endometriosis when the tumor presents as a benign
looking endometrioma. 
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Accepted : 17 March 2008On gross examination, the cervical wall of the uterus con-
tained a relatively well defined, cystic lesion filled with dark
brown fluid, measuring 3×2.2×2.2 cm. The dark brown
colored inner surface of the cyst showed multi-focal, papillary
growing, solid and granular masses, measuring up to 0.8×
0.8×0.5 cm (Fig. 2). Microscopically, these masses were com-
posed of well differentiated endometrioid adenocarcinoma,
which was directly adjacent to the epithelium of the endo-
metriotic cyst of the cervical wall. Transitional areas between
the glandular epithelium of the endometriosis and the endo-
metrioid adenocarcinoma cells were observed. There was no
invasion to the cervical stroma and no connection between
the overlying mucosal epithelium of the endo-ectocervix and
the epithelium of the endometriosis or the adenocarcinoma.
A secretory phase endometrium measured 0.8 cm in thick-
ness. There was no evidence of a primary endometrial or en-
docervical adenocarcinoma in the endocervix or endometrium
(Fig. 3). Multiple foci of endometriosis were present within
the posterior wall of the uterus and both ovaries. A serous
cystadenoma was also present in the right ovary, measuring
4.0 cm in greatest dimension.
The expression of estrogen and progesterone receptors, p53
and c-erb B-2 was analyzed using paraffin immunohistochem-
istry. The area of endometrioid adenocarcinoma was positive
for both estrogen and progesterone receptors. Weak expres-
sion of p53 and c-erbB2 (10-20% of nuclear staining) was
observed in the carcinomatous area. The patient was diag-
nosed as having an endometrioid adenocarcinoma arising from
endometriosis of the uterine cervix. Following recovery from
surgery, she was treated with six courses of chemotherapy,
consisting of cyclophosphamide 600 mg/m2 and cisplatin 50
mg/m2 every 4 weeks.
At the present time, she has been clinically free of disease
for 24 months since undergoing surgery.
DISCUSSION
Endometriosis of the cervix is generally regarded as a rare
lesion, but its incidence has been as high as 2.4% in some
series (8). Previous trauma to the cervix may contribute to
this condition. For example, cervical endometriosis has been
observed in 43% of postconization hysterectomy specimens
obtained from patients with cervical intraepithelial neopla-
sia (CIN) recurrence and other conditions (not endometrio-
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Fig. 1. MRI findings of the patient. On T1, T2W sagittal images (A, B), showing multiple round masses of variable size on the uterine cervix
(arrows). Adenomyosis was observed in the body of the uterus, but no enlarged lymph nodes or ascites was observed.
Fig. 2. Cut surface of the cervical wall showing well defined hem-
orrhagic solid lesions (arrow).
A Bsis) (9). Therefore, the increasing incidence of invasive cervi-
cal procedures may increase the incidence of endometriosis.
Cervical smears taken from most patients with cervical endo-
metriosis have shown glandular cellularity (10, 11). In con-
trast, a cervical smear taken from our patient before explo-
ration showed normal features. There was no invasion to the
stroma of the cervix, or to the mucosal layer of the endocervix
or exocervix.
Neoplastic transformation is a rare complication of endo-
metriosis, documented in 0.3-0.8% of patients with ovarian
endometriosis (7). Of 147 women with pelvic endometrio-
sis, only one had ovarian cancer arising from the endometrio-
sis (0.7%) (12). The risk of cancer arising from pre-existing
endometriosis has been estimated at 0.7% to 1.0% (1). Of
neoplasms complicating endometriosis, 75% arise in the ov-
aries, with the majority (almost 70%) being of endometri-
oid type.
Malignant ovarian tumors have been documented in wo-
men with endometriosis. Endometriosis-associated ovarian
cancer (EAOC) usually occurs in younger women, has favor-
able outcomes, and appears as either a low-grade tumor of
endometrioid cell type or as a clear cell tumor. As the patho-
logic features of “atypical endometriosis” may constitute a
precancerous state, women with atypical endometriosis may
be at an increased risk of developing EAOC. Malignant ch-
anges have also been diagnosed in extragonadal endometrio-
sis. For example, a survey of 45 extragonadal malignancies
associated with endometriosis in 1977 found that 16 (36%)
were in the rectovaginal area, 5 (11%) in the colorectal area,
4 (9%) each in the bladder and vagina, 3 (7%) in the pelvic
ligaments, and 2 (4%) each in the umbilicus, cervix, and fal-
lopian tube (13). A more recent survey of 27 malignancies
associated with endometriosis found that 17 (62%) were in
the ovary, 3 (11%) in the vagina, 2 (7%) each in the fallopian
tube or mesosalpinx, pelvic sidewall, and colon, and 1 (4%)
in the parametrium (14); this report, however, did not include
cervical malignancies associated with endometriosis. Malig-
nant transformation of extra-ovarian endometriosis is thought
to account for approximately 25% of all malignant transfor-
mations of endometriosis (1, 15).
Because of the rarity of malignant transformation of endo-
metriosis at extraovarian sites, including the cervix, it is dif-
ficult to design an optimal surgical procedure. When feasi-
ble, however, primary surgical treatment should consist of
complete resection of all disease containing tissue. Gross le-
sions in the pelvis should be surgically staged (1). Although
postoperative treatment has not been clearly defined, 70%
of these patients have been reported to receive chemothera-
py or radiotherapy after first line surgery (1, 15). 
The 5-yr survival rate for patients with estrogen-stimu-
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Fig. 3. Histopathological findings. (A) Dilated endocervical glands
in the cervix. There was no evidence of adenocarcinoma or con-
nection with the endometriotic cyst (H&E, ×40). (B) Direct conti-
nuity was observed from the endometriosis (left upper) to the endo-
metrioid adenocarcinoma (right side) in the cervix (H&E, ×100).
(C) High-power view of endometrioid adenocarcinoma in the cervix
(H&E, ×400).
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Blated endometriosis-associated neoplasms arising at all sites
has been reported to be 82% (1). Moreover, patients with
endometrioid adenocarcinoma coexisting with endometrio-
sis have a favorable prognosis (16).
To classify a malignancy as arising from endometriosis,
strict histopathologic criteria need to be met (17). These in-
clude the demonstration of cancer arising in the tissue and
not invading it from another source, and the presence of tis-
sue resembling endometrial stroma surrounding the epithe-
lial glands. Microscopic endometriosis contiguous with the
malignant tissue should also be demonstrated. Our patient
met all these diagnostic criteria. 
The risk factors for malignant transformation in endome-
triosis are poorly defined. Estrogen can stimulate the growth
of ectopic endometrial tissue. Thus, if any ovarian tissue re-
mains following a hysterectomy, the disease is likely to recur
in as many as 40% of women after 5 yr (6, 18). In addition,
an association has been noted between unopposed estrogen
therapy and the development of endometrioid or clear cell
epithelial ovarian tumors (19, 20). Of 21 women with extr-
aovarian cancers arising in endometriosis, 13 (62%) had re-
ceived hormone replacement therapy (HRT) (15). In contrast,
only 10% of other groups of patients, including those with
ovarian cancer arising within the endometriosis, ovarian can-
cer with adjacent endometriosis and ovarian cancer with inci-
dental endometriosis, had received HRT, with the majority
of the latter receiving unopposed estrogen. In addition, ta-
moxifen therapy has been associated with endometriosis and
the exacerbation of endometriotic foci in postmenopausal
women (21), and obesity may affect tumor development (22).
However, the body mass index of our patient was 24.4 kg/
m2 and she had no previous history of estrogen or tamoxifen
use. Also, our patient was 48 yr old and was premenopausal.
Of three women with malignant tumors arising in endom-
etriosis, 2 showed loss of ER and PR expression, suggesting
that these tumors lose hormonal responsiveness as a result of
malignant transformation (20). In contrast, the tumors in our
patient showed consistent ER and PR expression, and she had
no history of exposure to unopposed estrogen. These findings
suggest that the loss of hormonal responsiveness did not play
a part in the malignant transformation of endometriosis in
our patient.
The increased association of HRT use with extraovarian
cancer arising in endometriosis raises interesting questions
that should prompt further investigation. Patients with en-
dometrial cysts of the pelvic organs associated with high lev-
els of serum CA125 should be managed with special care,
even premenopausal women with no history of hormone ther-
apy. Further work is required to determine whether the dif-
ferences translate into a causal relationship. In conclusion, we
present an extremely rare case of endometriosis-associated ad-
enocarcinoma of the uterine cervix in a premenopausal woman.
The clinical behavior of these tumors is unpredictable and
long-term follow-up is essential in all patients. Additional
case reports and prospective studies are needed to determine
optimal treatment options to improve patient prognosis. 
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